Multiple actinic keratoses: a long-term approach
Prof. Piergiacomo Calzavara-Pinton
Research highlight
Managing multiple actinic keratoses (AKs) is a continuing process, not simply a single treatment followed by discharge. The presentation draws on a prospective observational cohort of 81 previously untreated patients, followed from 2012 to 2023 with assessments at six-month intervals and further treatment when needed.
Clearance after treatment did not consistently persist. Recurrent or newly apparent lesions led to repeated treatment cycles, while skin tumours continued to occur during follow-up. The central message is therefore to combine treatment with sustained surveillance, rather than assume that an initially good response ends the need for follow-up.
Treatment burden and continued care
The presentation also emphasises treatment burden and adherence: pain, inflammation and their duration can influence whether patients complete repeated courses. Discussing preferences and practical constraints is part of planning care that can be maintained over time.
How to interpret the evidence
This was an observational cohort, not a randomised comparison establishing which treatment is best. Its findings support a long-term perspective for this patient group; individual treatment choices still require clinical assessment and the relevant evidence.
Conclusion
ESPD editorial summary of previously published research discussed in the Vienna presentation. Not the full article, an EADV abstract or a new peer-reviewed publication.
Vienna contribution: 30 September 2026 · 10:20 CEST · Hall N · Vienna · EURO-PDT